Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Calithera Biosciences, Inc. (CALA)
|
Add to portfolio |
|
|
|
| Price: |
$0.68
| | Metrics |
| OS: |
4.87
|
M
| |
-386
|
% ROE
|
| Market cap: |
$3.3
|
M
| |
245
|
% ROIC
|
|
Net cash:
|
$34.1
|
M
| |
$7.00
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$11.8
|
M
| |
-2.6
|
x EV/EBITDA
|
|
EBIT
|
$11.5
|
M
| |
-2.7
|
x EV/EBIT
|
| EPS |
($4.72)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 9.8 | 0.0 | 0.0 | 22.3 | 26.0 | 0.0 | 0.0 | 0.0 |
| Revenue growth | | | -100.0% | -14.3% | | | | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 9.8 | 0.0 | 0.0 | 22.3 | 26.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | 100.0% | | | 100.0% | 100.0% | | | |
| Selling, general and administrative | 125.2 | 91.4 | 92.9 | | | | | |
| Research and development | 53.5 | 71.0 | 76.3 | 66.2 | 43.1 | 27.7 | 23.7 | 16.4 |
| General and administrative | | | | 13.3 | 12.5 | 10.6 | 9.1 | 5.4 |
| EBIT | -64.9 | -92.6 | -95.9 | -57.3 | -29.7 | -38.3 | -32.8 | -21.7 |
| EBIT margin | -665.7% | | | -257.4% | -114.4% | | | |
| Pre-tax income | -115.1 | -90.1 | -89.9 | -54.6 | -27.8 | -38.0 | -32.6 | -21.7 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -115.1 | -90.1 | -89.9 | -54.6 | -27.8 | -38.0 | -32.6 | -21.7 |
| Net margin | -1180.4% | | | -245.5% | -107.2% | | | |
| |
| Diluted EPS | ($1.56) | ($1.31) | ($1.90) | ($1.49) | ($0.84) | ($1.95) | ($1.81) | ($4.67) |
| Shares outstanding (diluted) | 73.9 | 68.8 | 47.3 | 36.6 | 33.0 | 19.5 | 18.0 | 4.7 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|